Mostrar el registro sencillo del ítem
dc.contributor.author | García Lunar, Inés | |
dc.contributor.author | Blanco Vich, Isabel | |
dc.contributor.author | Fernández Friera, Leticia | |
dc.contributor.author | Prat González, Susanna | |
dc.contributor.author | Jordà, Paloma | |
dc.contributor.author | Sánchez González, Javier | |
dc.contributor.author | Pereda, Daniel | |
dc.contributor.author | Pujadas, Sandra | |
dc.contributor.author | Rivas Lasarte, Mercedes | |
dc.contributor.author | García Álvarez, Ana | |
dc.contributor.author | Et al. | |
dc.date.accessioned | 2020-05-08T14:55:44Z | |
dc.date.available | 2020-05-08T14:55:44Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | García Lunar, I., Blanco Vich, I., Fernández Friera, L., Prat Gonzàlez, S., Jordà, P., Sánchez, J., Pereda, D., Pujadas, S., Rivas Lasarte, M., Solé González, E., Vázquez, J., Blázquez, Z., García Picart, J., Caravaca, P., Escalera, N., García Pavia, P., Delgado, J., Segovia Cubero, J., Fuster, V., … García Álvarez, A. (2020). Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial. JACC: Basic to Translational Science, 5(4), 317-327. https://doi.org/10.1016/j.jacbts.2020.01.009 | spa |
dc.identifier.issn | 2452-302X | |
dc.identifier.uri | http://hdl.handle.net/11268/8917 | |
dc.description.abstract | Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial | spa |
dc.type | article | spa |
dc.description.impact | 8.648 JCR (2020) Q1, 16/142 Cardiac & Cardiovascular Systems | spa |
dc.description.impact | 2.549 SJR (2020) Q1, 27/349 Cardiology and Cardiovascular Medicine | spa |
dc.description.impact | No data IDR 2020 | spa |
dc.identifier.doi | 10.1016/j.jacbts.2020.01.009 | |
dc.rights.accessRights | openAccess | spa |
dc.subject.uem | Hipertensión pulmonar | spa |
dc.subject.uem | Tratamiento médico | spa |
dc.subject.unesco | Aparato respiratorio | spa |
dc.subject.unesco | Enfermedad | spa |
dc.subject.unesco | Tratamiento médico | spa |
dc.description.filiation | UEM | spa |
dc.peerreviewed | Si | spa |